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BACKGROUND: Animal and human studies highlight the role of oxytocin in social cognition and behavior and the
potential of intranasal oxytocin (IN-OT) to treat social impairment in individuals with neuropsychiatric disorders such
as autism. However, extensive efforts to evaluate the central actions and therapeutic efﬁcacy of IN-OT may be
marred by the absence of data regarding its temporal dynamics and sites of action in the living human brain.
METHODS: In a placebo-controlled study, we used arterial spin labeling to measure IN-OT-induced changes in
resting regional cerebral blood ﬂow (rCBF) in 32 healthy men. Volunteers were blinded regarding the nature of the
compound they received. The rCBF data were acquired 15 min before and up to 78 min after onset of treatment
onset (40 IU of IN-OT or placebo). The data were analyzed using mass univariate and multivariate pattern recognition
techniques.
RESULTS: We obtained robust evidence delineating an oxytocinergic network comprising regions expected to
express oxytocin receptors, based on histologic evidence, and including core regions of the brain circuitry
underpinning social cognition and emotion processing. Pattern recognition on rCBF maps indicated that IN-OT-
induced changes were sustained over the entire posttreatment observation interval (25–78 min) and consistent with a
pharmacodynamic proﬁle showing a peak response at 39–51 min.
CONCLUSIONS: Our study provides the ﬁrst visualization and quantiﬁcation of IN-OT-induced changes in rCBF in
the living human brain unaffected by cognitive, affective, or social manipulations. Our ﬁndings can inform theoretical
and mechanistic models regarding IN-OT effects on typical and atypical social behavior and guide future
experiments (e.g., regarding the timing of experimental manipulations).
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ISShttp://dx.doi.org/10.1016/j.biopsych.2014.10.005Animal research has demonstrated that oxytocin (OT) plays a
key role in the development and regulation of mammalian
social behavior (1–7). In the absence of suitable radioligands,
designs using intranasal sprays to manipulate OT levels in the
brain (8) or to investigate the effects of polymorphisms in the
OT receptor gene (9) have conﬁrmed a similar role in humans
(10–17). An increasing number of clinical trials have explored
the therapeutic value of intranasal oxytocin (IN-OT) for neuro-
psychiatric disorders characterized by social impairment, such
as autism, schizophrenia, and anorexia, with promising initial
results (10,18–26). However, this effort is marred by the
absence of data relating to the pharmacodynamics of IN-OT
in the human brain.
As a consequence, studies still determine experimental
parameters based on assumptions derived from the temporal
proﬁle of changes in the concentration of vasopressin in the
cerebrospinal ﬂuid (CSF) after intranasal administration (27).
However, translating this work to studies using IN-OT faces
two obstacles. First, despite their structural similarity, vaso-
pressin and OT are different neuropeptides with distinct016 The Authors. Published by Elsevier Inc. on behalf of Society of Biolo
cle under the CC BY license (http://creativecommons.org/licenses/by/3.
N: 0006-3223 Bio
SEE COMMENTARYneurophysiology (8,28,29). Second, although the more recent
demonstration that IN-OT also increases CSF OT concen-
tration in adult male volunteers (30) is promising, there is
dissociation between the concentration of a neuropeptide in
the CSF and its availability in brain tissue (31). We need to
understand the temporal changes in brain physiology caused
by IN-OT to optimize future studies.
Equally, we need to understand the spatial distribution of
IN-OT effects in humans. There are three main reasons this
understanding is currently hindered. First, the distribution and
concentration of OT receptors underpin interspecies and
intraspecies differences in social behavior (32), precluding
direct translation of information across species. To date, the
sole evidence regarding the distribution of OT receptors in
human brain comes from the study of a small number of
postmortem brains of mainly elderly donors (33–35). Although
valuable, these studies provide only a static snapshot of a
dynamic system using radioligands for which the receptor
speciﬁcity is not fully determined (35,36). Second, task-based
blood oxygen level–dependent (BOLD) functional magneticgical Psychiatry. All rights reserved. This is an open access
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Psychiatryresonance imaging (fMRI) studies cannot address this ques-
tion because they identify relative changes between exper-
imental and control conditions and are not sensitive to a single
physiologic parameter (37,38). Consequently, any observed
effects are uniquely conﬁned to the neural network engaged in
a given task. Third, animal studies demonstrate that different
social stimuli may elicit different release proﬁles of endoge-
nous OT (28). Conclusions regarding changes in brain function
induced by IN-OT are limited to the stimulus class employed.
More recent “resting-state” BOLD fMRI studies have circum-
vented some of these issues by focusing on changes in
functional connectivity following IN-OT (39,40). Resting-state
fMRI provides a promising alternative but cannot quantify
changes in brain physiology directly.
We sought to understand the spatial and temporal proﬁle of
neurophysiologic changes in the 25–78 minutes following the
onset of IN-OT administration (compared with placebo) in
the human brain. We used arterial spin labeling (41,42) to
measure in vivo changes in brain physiology unaffected by
concomitant cognitive, affective, or social manipulations.
Arterial spin labeling is a noninvasive pharmacodynamic
biomarker (43–48) that provides quantitative measures of the
effects of acute doses of psychoactive drugs on regional
cerebral blood ﬂow (rCBF), with high spatial resolution and
excellent temporal reproducibility (37,43,49). Changes in rCBF
are likely to reﬂect changes in neuronal activity, rather than
simple vascular effects (50–55).
We expected to observe increases in rCBF over mainly
limbic areas previously identiﬁed to express OT receptors in
human postmortem brains (33–35) and brain areas involved in
social-emotional processing that are functionally linked with
regions expressing OT receptors, such as the insula and
inferior frontal gyrus (56–58). At least 100-fold higher afﬁnity
is shown by OT for OT receptors compared with vasopressin
receptors (29,36,59). We mapped the distribution of effects of
IN-OT using conventional mass univariate voxel-by-voxel
analysis, allowing inferences regarding local regions. In the
absence of an a priori pharmacodynamic model, we used
multivariate pattern recognition (PR) on rCBF maps (60)
to elucidate temporal dynamics. When the pharmacologic
intervention elicits correlated, spatially distributed effects
(37,44,45,61) as IN-OT does (28,62), PR offers increased
sensitivity compared with conventional mass univariate
approaches. The overall pattern of rCBF changes at each
temporal interval can be reduced by PR into a single metric—
the probability that an rCBF image belongs to a particular
class (here, IN-OT or placebo). Using these predictive proba-
bilities, we created pharmacodynamic proﬁles of changes in
brain physiology following IN-OT or placebo.METHODS AND MATERIALS
Participants
We recruited 32 healthy men (IN-OT group, n = 16, mean age
(SD) = 24.23 (1.75) years; placebo group, n = 16, mean age =
25.78 (4.44) years; t30 = 1.30, p = .21) based on previous
power analyses (63). Participants were screened for psychi-
atric conditions using Symptom Checklist-90-Revised (64) and
Beck Depression Inventory-II (65) questionnaires, did not take694 Biological Psychiatry April 15, 2016; 79:693–705 www.sobp.org/jany prescribed drugs, tested negative on a urine screening
test for drugs of abuse, and consumed ,28 units of alcohol
per week and ,5 cigarettes per day. Both parents of
participants were white European to reduce genetic back-
ground variability. Participants abstained from alcohol and
heavy exercise for 24 hours and abstained from any beverage
or food in the 2 hours before scanning in the morning.
Participants gave written informed consent. King’s College
London Research Ethics Committee (PNM/10/11-160)
approved the study.
Design, Materials, and Procedure
We employed a single-blinded, placebo-controlled design with
two independent study arms. Before taking part, all partic-
ipants were informed they would receive a neuropeptide and
remain blinded to its name and that they might receive
placebo until the postsession debrieﬁng; 50% received
IN-OT, and 50% received placebo. We obtained two baseline
cerebral blood ﬂow (CBF) images before participants came out
of the scanner to receive 40 IU of IN-OT (Syntocinon; Novartis,
Basel, Switzerland) or placebo (same composition as Synto-
cinon except for OT). We used 40 IU, the highest clinically
applicable safe dose administered to human volunteers [e.g.,
in 14% of studies until 2011 (66) and still being used (15)] to
maximize power. Use of this dose also ensured comparability
with the study of Born et al. (27) on vasopressin in the CSF
using 40 IU as the minimum dose.
Participants self-administered one puff (4 IU) of IN-OT (or
placebo) every 30 seconds, alternating between nostrils. The
administration phase lasted approximately 9 minutes including
a 3-minute rest at the end. Participants returned to the scanner
for two anatomic scans followed by eight CBF images
spanning 25–78 minutes from the onset (henceforth called
postadministration scans) of nasal spray administration
(Figure 1A). Participants were instructed to lie still and maintain
their gaze on a centrally placed ﬁxation cross during scanning.
We assessed participants’ levels of alertness (anchors: alert-
drowsy) and excitement (anchors: excited-calm) using visual
analog scales before acquiring each CBF image. The sub-
jective ratings of one participant from the IN-OT group were
lost because of a technical issue.
Image Acquisition and Preprocessing
Images were acquired using a Signa HDx 3.0T magnetic
resonance imaging scanner (General Electric, Milwaukee,
Wisconsin). We employed the pulsed-continuous arterial spin
labeling methodology (67). The CBF maps (in standard phys-
iologic units—mL blood/100 g tissue/min) were computed
with a spatial resolution of 1 mm 3 1 mm 3 3 mm. Total
acquisition time for each CBF map was 5.5 minutes. We also
acquired a T2-weighted fast spin echo high spatial resolution
structural image for coregistration and normalization
purposes.
We performed the following preprocessing steps (detailed
in the Supplement. 1) We removed extracerebral signal from
each participant’s T2 volume and created a binary brain mask.
2) We coregistered each CBF image to the corresponding T2
volume for each participant, correcting for interscan move-
ment. 3) We removed extracerebral signal from CBF images byournal
Figure 1. Experimental design, subjective ratings, and global cerebral blood ﬂow values (IN-OT group, n 5 16; placebo group, n 5 16). (A) Experimental
design. (B) Οverall, participants’ levels of alertness (IN-OT, z 5 2.57, p 5 .010; placebo, z 5 2.20, p 5 .028) and excitement (IN-OT, z 5 2.12, p 5 .034;
placebo, z 5 1.40, p 5 .16) linearly decreased over time. For VAS ratings, we measured the distance of the cursor from one extreme and converted to a score
ranging from 250 (alert/excited) to 50 (drowsy/calm), with 0 being the midpoint. (C) Global cerebral blood ﬂow values also linearly decreased over time (IN-OT,
z 5 22.82, p 5 .005; placebo, z 5 22.45, p 5 .014). Error bars represent SE. Corrected p values reported. BSL, baseline; IN-OT, intranasal oxytocin; MRI,
magnetic resonance imaging; rCBF, regional cerebral blood ﬂow; VAS, visual analog scale.
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the T2 volume to the Montreal Neurological Institute 2-mm T2
template, applying the transformation matrix to the coregis-
tered, brain-only CBF images. 5) We smoothed the CBF
images using an 8-mm Gaussian kernel. We restricted the
search volume to gray matter voxels only using an explicit
mask of voxels with a ..20 probability of being gray matter.
Global CBF Measures and Subjective Ratings
We extracted global CBF values using MarsBaR (http://
marsbar.sourceforge.net/). We conducted the following anal-
yses (Supplement): First, we performed a nonparametric test
for a linear change in global CBF signal and subjective ratings
over time (68). Second, we investigated the association
between changes in global CBF signal and self-ratings of
alertness and excitement over time. Finally, we tested for the
effect of treatment on subjective ratings and global CBF signal
(averaged over baseline and postadministration scans) with
the Treatment (IN-OT, placebo; between-subjects factor) 3Biological PPeriod (baseline, postadministration; within-subjects factor)
term in a mixed 2 3 2 analysis of variance model implemented
in Stata (version 13; StataCorp LP, College Station, Texas),
correcting for data dependence (69) and multiple testing using
the sequential Holm-Bonferroni correction procedure (70).
Whole-Brain Univariate Analyses: Mapping the
Spatial Proﬁle of IN-OT-Induced Changes in rCBF
We implemented an analysis of covariance design to control for
baseline differences (71) using a ﬂexible factorial model in
SPM8 software (http://www.ﬁl.ion.ucl.ac.uk/spm/software/
spm8/), specifying the factors Subjects, Treatment, and Period.
We used the Treatment 3 Period interaction term and an F
contrast to test for brain regions where IN-OT led
to changes in rCBF regardless of direction in the 25–78 minutes
after administration. We conducted cluster-level inferences at
α 5 .05, using familywise error (FWE) correction for multiple
comparisons from a voxel-level cluster-forming threshold of
Z . 2.3 (72). The required cluster size threshold for thesychiatry April 15, 2016; 79:693–705 www.sobp.org/journal 695
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using Analysis of Functional NeuroImages 3dClustSim (http://
afni.nimh.nih.gov/pub/dist/doc/program_help/3dClustSim.html).
To understand the nature of the effect, we extracted and plotted
the data from each of the identiﬁed clusters, adjusting for the
Treatment 3 Period contrast. To enhance the contrast between
rCBF at baseline and after administration, we included global
CBF values as nuisance covariates in the general linear model.
PR: Investigating Temporal Dynamics of the Spatial
Pattern of IN-OT-Induced Changes in rCBF
We restricted PR analyses to an a priori–deﬁned mask that
included brain regions likely to contain oxytocin receptors, based
on previous postmortem human brain studies (Supplement).
Brieﬂy, PR involves learning a pattern (a “model”) of brain voxels
that can distinguish rCBF images as being acquired before or
after treatment (our two “classes”). This trained model could be
used to assign a label to a new, previously unseen image
(“classiﬁcation”). This procedure is repeated N times, each time
using N-1 participants to learn the pattern (“training the model”)
and applying it to images from the Nth (“left-out”) participant
(“leave-one-out cross-validation” procedure). We used Gaussian
process classiﬁcation (GPC) (44,61,73) to estimate the probability
that a previously unseen image from the Nth participant belongs
to the posttreatment class (the “predictive probability”) (see the
Supplement for more information on the GPC). A predictive
probability..5 was used to assign an image to the posttreatment
class. The statistical signiﬁcance of the performance of the model
was estimated using permutations (i.e., repeating the above-
described procedure after randomly mixing the training image
labels 1000 times to test the null hypothesis that the performance
is not greater than chance [50%]—of no predictive value).696 Biological Psychiatry April 15, 2016; 79:693–705 www.sobp.org/jFigure 2 details a schematic representation of GPC analysis.
We averaged pairs of consecutive scans to improve the signal-
to-noise ratio, potentially improving classiﬁcation accuracy (45).
We used the predictive probabilities as the main outcome
measure and as a proxy to create a pharmacodynamic proﬁle of
the IN-OT perfusion effect. We compared scans after adminis-
tration with baseline for each study arm separately because the
administration of IN-OT and placebo to different individuals was
expected to inﬂate the between-group variance, obscuring the
sensitivity of GPC to the expected IN-OT effect. Cross-group
multivariate classiﬁcation was not part of our design (see
Supplemental Table S1 for results). However, to obtain a formal
measure of cross-group classiﬁcation performance, we imple-
mented a mixed Treatment 3 Period (using the seven post-
administration subperiods deﬁned by each possible pair of
consecutive rCBF images) analysis of variance on predictive
probabilities. Finally, we constructed maps to visualize the
distributed discriminative spatial pattern of multivariate weights
driving the classiﬁcation.
RESULTS
Global CBF Measures and Subjective Ratings
We observed a general linear decrease over time in partic-
ipants’ levels of alertness and excitement and in global CBF
values in both groups (Figure 1B, C and Supplemental
Results). Self-reported levels of alertness and excitement cor-
related with global CBF values (alertness, r 5 .16, p 5 .009;
excitement, r 5 .23, p , .001). This association and the
signiﬁcant global decrease in rCBF over time, which might
prevent the identiﬁcation of signiﬁcant changes in CBF in small
regions, provided a suitable rationale for including global CBFFigure 2. Schematic analysis
pipeline. (A) Experimental setup.
Indicative rCBF maps are presented
for illustration purposes. (B) Train-
ing and testing the Gaussian pro-
cess classiﬁer model on each
participant and an illustration of
the baseline–post nasal spray con-
tinuum. rCBF, regional cerebral
blood ﬂow.
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observe Treatment or Period effects on global CBF values
(Supplemental Results and Supplemental Table S2).
Univariate Analyses: Mapping Spatial Proﬁle of
IN-OT-Induced Changes in rCBF
The F contrast identiﬁed four clusters showing a signiﬁcant
Treatment 3 Period interaction in rCBF in the 25–78 minute
postadministration interval (Table 1 and Figure 3). Clusters
extended over a network of regions including 1) left hemisphere
limbic and midbrain/brainstem regions, including amygdala,
hippocampus, caudate nucleus, ventral striatum and pallidum,
septal and hypothalamic nuclei, substantia nigra, and pontine
brainstem nuclei; 2) bilateral dorsal anterior and middle cingulate
cortices; 3) inferior frontal gyrus, anterior insula, frontal and
parietal opercula, and superior temporal gyrus, extending to the
plana temporale and polare and the supramarginal gyrus in
inferior parietal cortex; and 4) right hemisphere cerebellum.
Directional T contrasts for the interaction effect identiﬁed the
same clusters (clusters 1 and 3, pFWE, .001, k5 7360; cluster 2,
pFWE 5 .019, k 5 2114; cluster 4, pFWE 5 .041, k 5 1767). We
extracted and plotted data from each of these clusters, observing
a crossover interaction pattern where the administration of IN-OT
increased rCBF in clusters 1–3 (compared with baseline), whereas
the reverse pattern was observed for the placebo group. The
opposite pattern was observed in the cerebellum (Figure 3).
PR Analyses: Investigating Temporal Dynamics of
IN-OT-Induced Changes in rCBF
Classiﬁcation Accuracies. The classiﬁcation accuracies for
the post IN-OT class (compared with the baseline class) were
.80% at all time intervals and signiﬁcantly different from chance.Table 1. Clusters Showing a Signiﬁcant Treatment 3 Period I
Interval (F Contrast)
Cluster Description H
Cluster 1
Caudate nucleus, ventral striatum, pallidum, amygdala,
hippocampus, septal nuclei, hypothalamus, ventral midbrain
(ventral tegmental area, substantia nigra), pontine tegmentum
L
Cluster 2
Anterior and middle cingulate cortices B
Cluster 3
Inferior frontal gyrus, anterior insula, planum polare, transverse
temporal gyrus, planum temporale, superior temporal gyrus, inferior
parietal cortex–supramarginal gyrus, frontal operculum, parietal operculum
L
Cluster 4
Cerebellum R
The required cluster size threshold at α = .05 was calculated to be k =
3dClustSim.
rCBF, regional cerebral blood ﬂow.
Biological PFor the post placebo class (compared with baseline), classiﬁcation
accuracies ranged from 38%–81% and did not differ signiﬁcantly
from chance except at the 32–44 minute interval (Table 2).
Predictive Probabilities. Statistical analysis of cross-
group classiﬁcation performance using the predictive probabil-
ities conﬁrmed the above-described pattern. We observed a
signiﬁcant main effect for Treatment (but not Period) and a
signiﬁcant Treatment 3 Period interaction (Table 3, Figure 4A).
Predictive probabilities were signiﬁcantly higher for the post
IN-OT class compared with post placebo class at 39–51
minute, 45–58 minute, and 52–65 minute intervals. Similarly,
there was an effect of Period in the post IN-OT but not the post
placebo group. Figure 4A shows that the averaged predictive
probabilities for the post IN-OT class peaked at the 39–51
minutes post IN-OT interval, followed by a gradual diminution
over time. Figure 4B shows the multivariate map of the
discriminative spatial pattern underpinning classiﬁcation at the
39–51 minute interval in the post IN-OT and placebo groups.DISCUSSION
Using arterial spin labeling as a pharmacodynamic biomarker
(43–48), we visualized and quantiﬁed, for the ﬁrst time in living
human brain, IN-OT-induced changes in rCBF unaffected by
concomitant cognitive, affective, or social manipulations. Con-
ﬁrming predictions from postmortem histologic studies (33–35),
we delineated an oxytocinergic network comprising regions
expected to express OT receptors and that are involved in social
cognition and emotion processing (56–58,74–76). Addressing the
lack of a temporal dynamics model for the human brain, GPC
indicated that IN-OT-induced changes in rCBF were sustained
over the posttreatment observation interval of 25–78 minutesnteraction in rCBF in the 25–78 minute Postadministration
Peak
Coordinates
emisphere k p x y z Description
eft 1999 ,.05 214 230 236 Dorsal midbrain
210 218 226 Ventral midbrain
210 4 2 Pallidum
ilateral 1539 ,.05 22 10 24 Anterior cingulate cortex
22 212 32 Middle cingulate cortex
eft 2816 ,.05 250 0 24 Superior temporal gyrus
258 222 0 Middle temporal gyrus
258 224 6 Superior temporal gyrus
ight 1244 ,.05 28 268 242 Cerebellum (lobule VIIa, crus II)
14 266 242 Cerebellum (lobule VIIIa)
44 256 250 Cerebellum (lobule VIIa, crus I)
1089 voxels, using the Analysis of Functional NeuroImages program
sychiatry April 15, 2016; 79:693–705 www.sobp.org/journal 697
Figure 3. Statistical parametric maps for the four clusters showing a signiﬁcant Treatment (intranasal oxytocin [n 5 16], placebo [n 5 16]) 3 Period (baseline,
after administration) interaction (F contrast) over the entire observation interval of 25–78 minutes following the onset of treatment. Inserted graphs plot the
extracted (ﬁrst eigenvariate), F contrast adjusted rCBF values for each cluster to illustrate the interaction effect. Error bars represent SE. The right-hand side of
each image corresponds to the participant’s right side. Slice numbers indicate Montreal Neurological Institute coordinates. rCBF, regional cerebral blood ﬂow.
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a pharmacodynamic proﬁle showing a peak response at 39–51
minutes, followed by a gradual diminution of effects.
Mapping the Oxytocinergic Network in the Human
Brain
The signiﬁcant Treatment 3 Period crossover interaction
identiﬁed cortical and subcortical regions showing higher
rCBF after treatment in the IN-OT group compared with the
placebo group, controlling for baseline differences. Most of the
subcortical limbic areas and the anterior cingulate gyrus have
been previously reported to express OT receptors in post-
mortem human brains (33–35). In the rat, OT receptors were
also identiﬁed in insular and temporal lobe regions (62,77), but
no evidence exists for humans.
The brain areas showing increased rCBF following IN-OT at
rest are part of a distributed “social brain” network (56–58,78–
84) (see the Supplement for a discussion of ﬁndings in relation to
the role of OT in centrally mediated physiologic functions). This
network underpins the processing of social and emotional
stimuli and the expression of social and afﬁliative behavior
(85–88). For example, it involves subcircuits such as the human
mirror system (80,82), those involved in cognitive and emotional698 Biological Psychiatry April 15, 2016; 79:693–705 www.sobp.org/jempathy (78,79,81,83,84) or theory of mind and mentalizing (89)
(Supplement). Neural activity in this network is consistently
modulated by an acute dose of IN-OT during social tasks
(10,39,90–102) and has been linked to differences in peripheral
OT levels (103). A meta-analysis of studies involving the
processing of emotional stimuli showed that IN-OT increased
BOLD signal over a single cluster centered on the left insula,
extending into the superior temporal and paracentral gyri (104).
Additionally, IN-OT enhanced neural activity within the oxyto-
cinergic network in children with autism spectrum disorder while
making social judgments (23). A single IN-OT dose (compared
with placebo) also modulates functional connectivity between
nodes of the oxytocinergic network when participants engage in
tasks requiring social cognitive or emotional processing (10,90–
102) or are at rest (39). For example, Striepens et al. (105)
reported that IN-OT (compared with placebo) enhanced func-
tional connectivity among the left amygdala, left anterior insula,
and left inferior frontal gyrus, whereas Riem et al. (40) reported
increased functional connectivity among the cingulate and
somatosensory cortices and the cerebellum.
The reverse pattern was shown by rCBF changes in the
right posterior cerebellar lobules: rCBF decreased after IN-OT
treatment compared with placebo. These cerebellar lobulesournal
Table 2. Performance Parameters for the Gaussian Process
Classiﬁcation Model
Contrast Accuracy pa
Sensitivity
(%)
Speciﬁcity
(%)
Predictive p
(Postnasal
Spray | rCBF
Map)
(M 6 SE)
Post IN-OT Class
25–38 min .83 ,.001 81.25 81.25 .69 6 .05
32–44 min .83 ,.001 81.25 81.25 .73 6 .05
39–51 min .94 ,.001 93.75 93.75 .80 6 .03
45–58 min 1.00 ,.001 100.00 100.00 .77 6 .03
52–65 min .88 ,.001 87.5 87.5 .73 6 .04
59–71 min .88 ,.001 87.5 87.5 .71 6 .05
66–78 min .83 ,.001 81.25 81.25 .70 6 .05
Post Placebo Class
25–38 min .69 ..05 68.75 68.75 .64 6 .05
32–44 min .81 ,.001 81.25 81.25 .66 6 .05
39–51 min .63 ..05 62.5 62.5 .62 6 .05
45–58 min .69 ..05 68.75 68.75 .58 6 .05
52–65 min .38 ..05 37.5 37.5 .55 6 .05
59–71 min .56 ..05 56.25 56.25 .59 6 .05
66–78 min .63 ..05 62.5 62.5 .61 6 .05
Performance of the Gaussian process classiﬁcation was assessed
using the leave-one-out procedure; statistical signiﬁcance of the
classiﬁcation accuracies was determined by random permutation
and adjusted for multiple testing using the Holm-Bonferroni correction
procedure.
IN-OT, intranasal oxytocin; rCBF, regional cerebral blood ﬂow.
aHolm-Bonferroni corrected values.
Table 3. Treatment 3 Period ANOVA on Predictive Prob-
abilities Computed Using Gaussian Process Classiﬁcation
on rCBF Maps
χ2a dfa p
Predictive Probabilities
Treatment 5.43 1 .02
Period 7.34 6 .29
Treatment 3 Period 13.59 6 .035
Simple Effects Analysesb
Treatment effect at 25–38 min .49 1 .49
Treatment effect at 32–44 min .94 1 .66
Treatment effect at 39–51 min 8.81 1 .018
Treatment effect at 45–58 min 9.98 1 .011
Treatment effect at 52–65 min 6.97 1 .042
Treatment effect at 59–71 min 3.44 1 .25
Treatment effect at 66–78 min 1.69 1 .58
Period effect in IN-OT group 15.06 6 .040
Period effect in placebo group 10.16 6 .12
ANOVA, analysis of variance; IN-OT, intranasal oxytocin; rCBF,
regional cerebral blood ﬂow.
aThe bootstrap procedure in Stata uses χ2 statistics to test for
statistical signiﬁcance, which we report (equivalent F values can be
obtained by dividing the χ2 statistic by its degrees of freedom).
bReported p values are adjusted for multiple testing using the
sequential Holm-Bonferroni correction procedure.
Cerebral Blood Flow Changes After Oxytocin
Biological
Psychiatryshow strong functional connections with cerebral limbic
association networks and networks related to executive con-
trol (106). This right laterality is consistent with the predom-
inantly contralateral cerebral-cerebellar mappings (106,107)
and the notable asymmetry in functional specialization in the
cerebellum (108). A low OT concentration (109) and the
projection of afferent OT ﬁbers (62) in the cerebellum have
been reported in rats, but there is currently no evidence in
humans. However, the cerebellum is increasingly being rec-
ognized to play an important role in aspects of social cognition
requiring high levels of abstraction in humans (110). This role is
consistent with the presence of anatomic and functional
cerebellar abnormalities in autistic spectrum disorders in
which social dysfunction is one of the core symptoms (111).
Further studies are required to elucidate the exact causes of
the observed IN-OT effects in rCBF in the cerebellum.
Changes in rCBF at rest induced by IN-OT showed a
predominantly left hemisphere laterality (and consistently with a
contralateral cerebral-cerebellar mapping, the right cerebellum).
This ﬁnding is remarkably consistent with the meta-analytic
evidence that IN-OT modulated activity over a speciﬁcally left
hemisphere network during processing of emotional stimuli (104).
These regions were also part of the maternal brain network
responding to visual or auditory stimuli of the mother’s own
(compared with unknown) children (104). The mammalian brain,
from humans to mice, shows a left hemisphere advantage
in processing species-speciﬁc communication sounds (112).
Resting-state fMRI and task-based studies have also reported
hemispheric asymmetries regarding the modulatory effects ofBiological PIN-OT on amygdala functional connectivity (105) or amygdala
response involving left (92,98,113,114) or right amygdala laterality
(97,100,101). These ﬁndings might be consistent with the noted
functional asymmetry in the amygdala, with right amygdala
involved in the rapid, automatic recognition of threatening stimuli
and left amygdala involved in the conscious perception and
regulation of the level of the emotional response (115). The
reported effects of IN-OT in left amygdala in the resting state
may relate to the anxiolytic effects of IN-OT in humans (116). A
similar left hemisphere laterality has been reported regarding
IN-OT modulatory effects in the striatum and frontal and temporal
cortex regions (92,98,113,114), and several nodes in the social
brain network [e.g., inferior parietal cortex (117) or inferior frontal
gyrus (74,118)]. The left hemisphere bias regarding IN-OT effects
on brain function might reﬂect the known lateralization of key
cognitive processes required for life in large social networks, such
as communication skills and group membership categorization, to
the left hemisphere (119).
Existing histologic evidence from postmortem human brains
cannot illuminate the observed asymmetries in the functional
effects of IN-OT. Early studies did not report the hemispheric
origin of their samples (33,34); a later study included some
bilateral but mostly left hemisphere samples (35). Genetic
imaging studies that investigate the effects of polymorphic
variation in the OT receptor gene on brain structure (120–124)
and function (122,123,125–130) might shed further light. How-
ever, to date, there are too few studies and too great a range of
tasks for a consistent pattern to emerge. Overall, these studies
involve the same cortical and subcortical regions composing the
oxytocinergic network identiﬁed here, including bilateral (e.g.,
anterior cingulate cortex) (123,127) or predominantly left hemi-
sphere (122,125,126,128,130) and right cerebellum effects
(Supplement) (127).sychiatry April 15, 2016; 79:693–705 www.sobp.org/journal 699
Figure 4. Pattern recognition analyses. (A) Estimated marginal mean predictive probabilities for the post nasal spray administration class (y axis) (and 95%
conﬁdence intervals) for the Treatment (IN-OT [n 5 16], placebo [n 5 16]) 3 Period (baseline, after administration) interaction as a function of time interval,
using an a priori deﬁned mask of brain regions likely to express oxytocin receptors. Note the temporal overlap between adjacent time intervals; to sample
the entire postoxytocin period, we averaged all pairs of adjacent regional cerebral blood ﬂow maps. We observed a signiﬁcant main effect for Treatment
[χ2 1 5 5.43, p 5 .020], but not for Period [χ2 6 5 7.34, p 5 .29], and a signiﬁcant Treatment 3 Period interaction [χ2 6 5 13.59, p 5 .035] (corrected p values
reported). The mean predictive probabilities for the post–IN-OTclass followed a pharmacodynamic proﬁle showing a peak response at 39–51 minutes,
followed by a gradual diminution of effects. (B) Multivariate maps of normalized weight vectors from the Gaussian process classiﬁcation (g-maps) at the 39–51
minute interval that contrast the post–IN-OT/placebo classes to the baseline class. Positive coefﬁcients (red color scale) indicate a positive contribution to the
prediction for each class, and negative coefﬁcients (blue color scale) indicate a negative contribution. A positive g-map coefﬁcient for a particular voxel
indicates a higher overall β weight for the post–IN-OT/placebo class, and similarly a negative g-map coefﬁcient indicates a higher overall β score for the
baseline class. A region with a high weight cannot be interpreted as driving the classiﬁcation; the whole pattern of weights drives the classiﬁcation. These
maps cannot be used to make inferences about local activation. The right-hand side of each image corresponds to the participant’s right side. Slice numbers
indicate Montreal Neurological Institute coordinates. (C) The a priori deﬁned mask of brain regions likely to express oxytocin receptors included the
subcallosal area (including basal forebrain regions), nucleus accumbens, caudate nucleus, putamen, globus pallidus, amygdala, hippocampus, thalamus, and
hypothalamus. The hypothalamus was deﬁned with a sphere centered on Montreal Neurological Institute coordinates (x y z: 0, 24, 28) using a 12-mm radius
(146,147). The remaining regions of interest were deﬁned using the Harvard-Oxford cortical and subcortical structural atlases in FSLview (http://fsl.fmrib.ox.
ac.uk). CI, conﬁdence interval; IN-OT, intranasal oxytocin; rCBF, regional cerebral blood ﬂow.
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Human Brain Physiology
The application of GPC on rCBF maps reﬂecting the distrib-
uted effects of IN-OT or placebo yielded two main ﬁndings.
First, classiﬁcation accuracies were signiﬁcant for scans after
administration compared with baseline scans at all temporal
intervals for the IN-OT group, but not the placebo group:
predictive probabilities for the former were signiﬁcantly higher
than predictive probabilities for the latter. This ﬁnding sug-
gests that IN-OT-induced changes in rCBF—and hence700 Biological Psychiatry April 15, 2016; 79:693–705 www.sobp.org/jneuronal metabolism (131) and activity (50–53,55)—were
sustained over the entire observation interval.
Physiologically, this ﬁnding is consistent with evidence from
animal studies that endogenous or exogenous OT binds
on hypothalamic OT-secreting neurons initiating energy-
demanding processes that induce prolonged effects on phys-
iology and behavior that last .1 hour (28,29,132,133). Human
studies provide indirect support: an acute dose of IN-OT
(compared with placebo) leads to an elevated concentration
of OT in the CSF at 75 minutes in adult male volunteers (30)
and for 7 hours after administration in saliva (134,135),ournal
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forward loop. However, the peripheral and central release of OT
are dissociated (28); plasma and CSF OT levels do not
correlate in humans (136–139), and peripheral OT cannot cross
the blood-brain barrier in sufﬁcient quantities to induce central
changes (140). Our ﬁndings suggest that changes in rCBF
provide a quantiﬁable, reliable index to link peripheral changes
in OT concentration with central effects following IN-OT.
Our second ﬁnding was that the temporal proﬁle of IN-OT-
induced rCBF changes showed a peak response 39–51 minutes
after IN-OT, followed by a gradual diminution of effects. This
ﬁnding matches the slow pharmacokinetics of OT in the CSF
(141) and is remarkably consistent with the dynamic changes in
OT concentration in the extracellular ﬂuid in the amygdala and
hippocampi in rodents that peaked 30–60 minutes after the
intranasal application of OT (31). The release of endogenous OT
also shows a similar pattern in rodents when triggered with alpha-
melanocyte-stimulating hormone, peaking 20–30 minutes after
stimulation (133).
Limitations
Using independent groups for the IN-OT and placebo arms and
concealing the identity of the nasal spray until debrieﬁng offered
protection against OT-related expectation effects (e.g., as might
have arisen from differential exposure to media hype about
expected outcomes of OT). In a crossover design, the absence
of perceivable changes in subjective experience following IN-OT
(66) might have led participants to think that they had received
placebo. However, our independent groups design may have
inﬂated the between-subject variance, which precluded cross-
group PR. Given the nature of this study, conducted at rest and
by treatment-naïve radiographers, with minimal interaction
between the main investigator and participants, a single-blind
design (where the main investigator was not naïve regarding the
administered compound) was deemed sufﬁcient. Finally, we
focused on male participants because some degree of sexual
dimorphism in the OT system (92,97,142) may be expected, and
most participants in experimental studies (66) and clinical trials
[e.g., in autistic spectrum disorders (19–23,25)] are male, aiming
to maximize the applicability and resource efﬁciency for this
novel study. Our ﬁndings need to be replicated in a double-
blinded, crossover design including both genders.
Conclusions
Our ﬁndings are consistent with animal evidence and extend this
evidence to humans. Our ﬁndings provide the experimenter and
clinician with direct evidence to guide decision making, guide
research in the pharmacokinetics and pharmacodynamics of IN-
OT, and inform the development of theoretical and mechanistic
accounts regarding effects of OT on typical and atypical social
behavior. The power of arterial spin labeling to quantify the
effects of IN-OT on brain physiology renders it a promising,
noninvasive, in vivo method to investigate the impact of genetic
(9,143), epigenetic (126), social-environmental (40), and contex-
tual (144) factors on the baseline function of the OT system.
Additionally, the quantiﬁcation of IN-OT effects on brain phys-
iology will allow the establishment of dose-response associa-
tions between achieved effects on neurophysiology and
behavior or clinical symptoms. This information will contributeBiological Pto enhancing the validity and reliability of clinical trials inves-
tigating the therapeutic potential of IN-OT and cannot be
obtained using the nominal dosage of extant nasal sprays
because it does not reliably reﬂect tissue absorption (145).
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